Acorda Therapeutics Announces Delisting from Nasdaq
- None.
- Delisting from Nasdaq due to non-compliance with listing rules and Chapter 11 proceedings
- Failure to maintain stockholders' equity of at least $10 million
- Trading suspended on Nasdaq on April 12, 2024
The delisting of Acorda Therapeutics represents a significant shift in the company's financial stability and accessibility to investors. Delisting typically occurs when a company fails to meet the exchange's stringent financial and regulatory requirements. Acorda's Chapter 11 proceedings indicate it is attempting to reorganize its debts, which often leads to a reassessment of the company's operational strategy and financial health.
For stakeholders, this transition from Nasdaq to the OTC Pink Open Market generally entails a decrease in liquidity, potentially leading to more volatile stock prices and less stringent financial reporting requirements. Investors might experience difficulty buying or selling shares and may face increased risks. Long-term, the company's ability to raise capital may be challenged, necessitating a critical evaluation of their business rebound strategy and subsequent execution.
The legal ramifications surrounding Acorda's delisting due to non-compliance with Nasdaq's Listing Rules are indicative of significant underlying issues. Chapter 11 proceedings provide companies with protection while they restructure their debt, suggesting that Acorda has substantial financial hurdles. This process requires intricate legal maneuvering and can affect investor confidence due to the uncertainty over the company's future structure and operations.
Shareholders should be aware of their positions during this restructuring. Typically, common stocks may be devalued or wiped out as creditors are prioritized. This event should remind investors of the legal complexities inherent in restructuring and the potential implications for their holdings.
The effect of Acorda's delisting on the broader market and its sector could be minimal if it's a smaller player. However, it may reflect broader challenges within the pharmaceutical sector, particularly for companies facing financial management issues or those with a risky drug pipeline. It's critical to assess if this is an isolated incident or part of a larger trend of financial distress within the sector.
Investors often look to market listings as a stamp of credibility and stability. When a company is delisted, it's seen as a red flag, potentially causing a ripple effect on peer companies' valuations and investor perceptions, especially those with similar risk profiles.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
Forward-Looking Statements
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: our ability to negotiate and confirm a sale of substantially all of our assets under Section 363 of the Bankruptcy Code (or any other plan of reorganization); the high costs and related fees of cases instituted under the Bankruptcy Code; our ability to obtain sufficient financing to allow us to operate our business during the course of the Chapter 11 proceedings; our ability to satisfy the conditions and milestones in the Restructuring Support Agreement; our ability to maintain our relationships with our suppliers, service providers, customers, employees and other third parties; our ability to maintain contracts that are critical to our operations; our ability to execute competitive contracts with third parties; the ability of third parties to seek and obtain court approval to terminate contracts and other agreements with us; our ability to retain our current management team and to attract, motivate and retain key employees; the ability of third parties to seek and obtain court approval to convert the Chapter 11 proceedings to a proceeding under Chapter 7 of the Bankruptcy Code; the actions and decisions of our shareholders, creditors and other third parties who have interests in the Chapter 11 proceedings that may be inconsistent with our plans; our ability to successfully market INBRIJA, AMPYRA, FAMPYRA or any other products that we may develop; our ability to attract and retain key management and other personnel, or maintain access to expert advisors; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures and take other actions which are necessary for us to continue as a going concern; risks related to the successful implementation of our business plan, including the accuracy of our key assumptions; risks related to our corporate restructurings, including our ability to outsource certain operations, realize expected cost savings and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA, AMPYRA or FAMPYRA to meet market demand; our reliance on third-party manufacturers for the production of commercial supplies of INBRIJA, AMPYRA and FAMPYRA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA, AMPYRA or FAMPYRA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and FAMPYRA outside the
These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415205418/en/
Tierney Saccavino
tsaccavino@acorda.com
Source: Acorda Therapeutics
FAQ
Why is Acorda Therapeutics being delisted from Nasdaq?
What is the new ticker symbol for Acorda Therapeutics on the OTC Pink market?
When was trading in Acorda Therapeutics' common stock suspended on Nasdaq?
Where is Acorda Therapeutics' common stock now quoted after delisting from Nasdaq?
